Eli Lilly had a lucrative first-quarter 2022, with revenue growth rising 15 percent driven by sales of the company’s diabetes drug Trulicity and its COVID-19 antibodies.
While food shortage and malnutrition have been a common scenario throughout human history, the worldwide public health crisis caused by the epidemic of obesity is relatively recent.
Building on Novo Nordisk’s success during June 2021 in obtaining the first drug approval for weight management since 2014, the Danish pharma giant is partnering with biotech company EraCal Therapeutics to develop new obesity-related drug targets.
A new study shows the persistent syndrome of Covid-19 after-effects known as long Covid can develop after “breakthrough” infections in vaccinated people. Other new findings suggest a gene that helps the coronavirus reproduce itself might contribute to life-threatening Covid-19 in young, otherwise healthy people.
A study in Science shed new light on the global epidemic obesity by evaluating nearly 650,000 exomes from the United Kingdom, United States and Mexico and identifying those with strong implications for body mass or obesity.
Germany’s Boehringer Ingelheim partnered with Denmark’s Zealand Pharma A/S to study the GLP-1/glucagon dual agonist BI 456906 in two Phase II trials as a potential treatment for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH).
Adult obesity is rising in the United States – with a greater impact on racial and ethnic minorities – a U.S. Centers for Disease Control (CDC) report showed, at a time when the health condition is seen causing heightened risk for severe Covid-19.
Pliant Therapeutics and Novartis reached a strategic collaboration and license deal to develop and commercialize integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis (NASH).
